Baicheng Medicine (301096.SZ) has disclosed its performance forecast for the first half of 2025. The company anticipates net profit attributable to shareholders will plummet to between 0 and 6 million yuan, reflecting a steep year-on-year decline of 95.53% to 100%. Moreover, after excluding non-recurring gains and losses, it projects a net loss ranging from 9 million yuan to 15 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments